High Risk Stocks To Buy 2017 -

: Another biotech leader, Nektar returned 387% following positive news regarding its immuno-oncology and painkiller treatments.

: The maker of Invisalign benefited from a near-monopoly on invisible braces, seeing a 131% increase as it expanded its training to thousands of dentists globally. high risk stocks to buy 2017

: This biotechnology firm was a standout, posting a 426% return in 2017. Its growth was driven by positive clinical trial results for its cholesterol-reducing drug candidate. : Another biotech leader, Nektar returned 387% following

The following stocks represented some of the most successful speculative plays for the year: : Another biotech leader

: Despite a "chaotic news cycle," markets remained remarkably steady, allowing growth premiums to outperform value premiums significantly.